Johnson & Johnson — JNJ
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $213.65 | $514.75B | 20.6 | 18.6 | 11.7% | 10.6% | $5.20 2.4% | 6.5 |
Latest Headlines
- · Sector Update: Health Care Stocks Softer Late Afternoon
- · Sector Update: Health Care Stocks Decline Tuesday Afternoon
- · Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight
- · JPM26: J&J leans on immunology launches to fuel annual growth
- · Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer
- · JPM26: J&J reveals oncology strategy
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2021-12-31 | $78.7B | $20.9B | $7.93 | N/A | N/A | N/A |
| 1 | 2022-12-31 | $80.0B | $17.9B | $6.86 | 1.6% | -14.1% | -13.5% |
| 2 | 2023-12-31 | $85.2B | $35.2B | $14.60 | 6.5% | 95.9% | 112.8% |
| 3 | 2024-12-31 | $88.8B | $14.1B | $5.84 | 4.3% | -60.0% | -60.0% |
| 4 | TTM 2025-03-31 | $89.3B | $21.8B | $8.99 | 0.6% | 55.1% | 53.9% |
| 5 | Average | 3.2% | 19.2% | 23.3% |
EPS
Forecasts
Y/Y % Change
JNJ Year-over-Year Growth
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 1.6% | 6.5% | 4.3% | 5.5% | 5.0% | 4.6% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 6 | 6 | |
| EPS Growth (%) | -14.1% | 95.9% | -60.0% | 85.8% | 5.9% | 22.7% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 8 | 8 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) | Personnel ($) |
|---|---|---|---|---|---|---|---|
| 2021 | $78.7B | $16.0B | $14.3B | $20.1B | $20.1B | $7.4B | $-600.0M |
| 2022 | $80.0B | $17.6B | $14.1B | $20.2B | $20.2B | $7.0B | $-1.2B |
| 2023 | $85.2B | $19.1B | $15.1B | $20.1B | $20.1B | $7.5B | $-1.4B |
| 2024 | $88.8B | $20.1B | $17.2B | $22.0B | $22.0B | $7.3B | $-900.0M |
| TTM | $92.1B | $22.0B | $15.7B | $22.9B | $22.9B | $7.4B | $-500.0M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | G&A Change (%) | SG&A Change (%) | Facilities / D&A Change (%) | Personnel Change (%) |
|---|---|---|---|---|---|---|---|
| 2022 | 1.59 | 10.08 | -0.99 | 0.64 | 0.64 | -5.68 | 100.00 |
| 2023 | 6.46 | 8.18 | 6.72 | -0.66 | -0.66 | 7.40 | 16.67 |
| 2024 | 4.30 | 5.59 | 14.23 | 9.23 | 9.23 | -1.96 | -35.71 |
| TTM | 3.75 | 9.42 | -8.83 | 4.13 | 4.13 | 0.67 | -44.44 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $193,389M |
| 1 | Cash | $18,577M |
| 2 | Total Liabilities | $114,916M |
| 3 | Total Debt | $50,761M |
| 4 | Total Equity | $78,473M |
| 5 | Debt to Equity Ratio | 0.65 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $213.65 | 4.2% | FINVIZ Growth: 8% | Nicks: 7 Finviz: 14 |
Nick's: 0.000 | 5.6 | 20.6 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $10.36 EPS | TTM | $67.66 | -68.3% | $144.16 | -32.5% |
| $10.85 EPS | 2025 | $70.86 | -66.8% | $150.98 | -29.3% |
| $11.49 EPS | 2026 | $75.04 | -64.9% | $159.88 | -25.2% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 10.70% | 9.65% | 10.71% | 9.66% | 0.48% | 0.77% | 11.49% | 10.37% | 98.0% | 85.9% |
| 3 Years | 10.70% | 9.65% | 10.71% | 9.66% | 0.48% | 0.77% | 11.49% | 10.37% | 98.0% | 85.9% |
| 5 Years | 10.70% | 9.65% | 10.71% | 9.66% | 0.48% | 0.77% | 11.49% | 10.37% | 98.0% | 85.9% |
| 10 Years | 10.70% | 9.65% | 10.71% | 9.66% | 0.48% | 0.77% | 11.49% | 10.37% | 98.0% | 85.9% |